This page shows the latest Eklira news and features for those working in and with pharma, biotech and healthcare.
It follows a similar deal agreed in July last year for AZ to buy the global respiratory portfolio of Almirall for $2bn, including the approved Eklira (aclidinium) for COPD and several
Almirall's franchise includes Eklira (aclidinium), LAS40464 (a combination of aclidinium with formoterol, which has been filed in Europe), LAS100977 (abediterol), a once-daily phase II long-acting beta2-agonist (LABA),
under 22m on the back of high roll-out costs for new products such as Sativex (nabiximols) for spasticity in multiple sclerosis (MS) and chronic obstructive pulmonary disorder (COPD) treatment Eklira
IQWiG knocks back Almirall's Eklira. Decides added benefit of COPD drug is not proven. ... A long-acting bronchodilator, Eklira is licensed to treat adults with chronic-obstructive pulmonary disease (COPD) and works by widening their narrowed airways.
sold as Eklira and Bretaris Genuair.
COPD) treatment Eklira/Tudorza (aclidinium bromide).
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Eklira and Duaklir. Business unit acquisition. 3, 075. Pfizer / Merck KGaA.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...